Severe neurologic complications of immune checkpoint inhibitors: a single-center review

ConclusionIn this clinical practice study, the incidence of neurologic IRAEs from ICIs was 0.95%. Although rare, neurologic IRAEs can be highly variable and severe, and patients with combination immunotherapy appeared to suffer more severe IRAEs. Neurologists play an important role in the early identification and management of IRAEs to reduce long-term morbidity and mortality.
Source: Journal of Neurology - Category: Neurology Source Type: research